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Abstract
Background: Acute and chronic inflammation play essential roles in inflammatory/autoimmune conditions.
Protective anti-inflammatory effects of the n-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) were reported in animal models of colitis, sepsis, and stroke. Since dendritic cells (DC) represent the essential
cellular link between innate and adaptive immunity and have a prominent role in tolerance for self-antigens, we
sought to investigate the impact of DHA on DC maturation and proinflammatory cytokine production.
Methods: Murine bone marrow-derived DC were treated with DHA and stimulated with various toll-like receptor
(TLR) ligands. Flow cytometry was used to determine the levels of surface maturation markers and endocytic
activity. Cytokine expression and secretion were measured by real-time RT-PCR and ELISA assays. PPARg and NFB
activity in nuclear extracts were determined by binding to specific oligonucleotide sequences using ELISA-based
assays. In vivo effects of DHA were assessed in splenic DC from LPS-inoculated mice maintained on a DHA-
enriched diet.
Results: DHA maintained the immature phenotype in bone marrow-derived DC by preventing the upregulation of
MHCII and costimulatory molecules (CD40, CD80 and CD86) and maintaining high levels of endocytic activity. DHA
inhibited the production of pro-inflammatory cytokines, including the IL-12 cytokine family (IL-12p70, IL-23, and IL-
27), from DC stimulated with TLR2, 3, 4, and 9 ligands. DHA inhibition of IL-12 expression was mediated through
activation of PPARg and inhibition of NFBp65 nuclear translocation. DHA exerted a similar inhibitory effect on IL-
12 and IL-23 expression in vivo in LPS-inoculated mice maintained on a DHA-enriched diet.
Conclusions: Exposure of bone marrow-derived DC to DHA resulted in the maintenance of an immature
phenotype and drastic reduction in proinflammatory cytokine release. DHA inhibited the expression and secretion
of the IL-12 cytokine family members (IL-12p70, IL-23 and IL-27), which play essential roles in the differentiation of
the proinflammatory Th1/Th17 effector cells. The effect of DHA on IL-12 expression was mediated through
activation of PPARg and inhibition of NFB. Inhibition of IL-12 and IL-23 expression was also evident in splenic DC
from mice fed a DHA-enriched diet, suggesting that dietary DHA acts as an anti-inflammatory agent in vivo.
Background
In contrast to n-6 polyunsaturated fatty acid (PUFAs)
such as arachidonic acid (AA) which mediate predomi-
nantly proinflammatory effects, the n-3 PUFAs are
mostly anti-inflammatory. The anti-inflammatory effects
of docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA) have been attributed initially to the
inhibition of COX mediated metabolism of AA. More
recently, DHA and EPA were shown to be the precur-
sors of potent anti-inflammatory derivatives such as
resolvins and protectins [reviewed in [1-8]].
DHA and EPA are obtained primarily from diet but
are also synthesized endogenously in the liver from a-
linoleic acid through a series of desaturation and elonga-
tion reactions. Circulating free fatty acids enter cells, fol-
lowed mostly by esterification via acyl-CoA transferase
into membrane-residing 2-lysophospholipids [4,8]. It has
been proposed that following proinflammatory signaling,
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cium-independent phospholipase and processed by 15-
lipoxygenases (15-LOX) into protectins and D-series
resolvins [reviewed in [4,9]]. In addition, circulating n-3
fatty acids also represent an important source of anti-
inflammatory mediators, as reported in a recent study
showing rapid accumulation of circulating DHA and
EPA in peritoneal inflammatory exudates [10].
Most of the studies related to the anti-inflammatory
activities of n-3 fatty acid derivatives, i.e.r e s o l v i n sa n d
protectins, have been focused on their effect in resolving
inflammation mostly through reduction in neutrophil
trafficking and upregulation of macrophage-mediated
removal of apoptotic cells [reviewed in [6,9,11,12]]. Few
studies reported effects of n-3 fatty acids on dendritic
cells (DC) [13-15]. DC represent the essential cellular
link between innate and adaptive immunity. Resident DC
activated by pathogens exhibit high endocytic capacity.
Following TLR signaling, conventional DC upregulate the
expression of MHC and costimulatory molecules, pro-
duce proinflammatory cytokines and chemokines, and
undergo a change in chemokine receptors. As a result,
activated DC migrate to lymph nodes where they stimu-
late naïve cognate T cells. In addition, DC can also func-
tion as inducers and maintainers of tolerance to self
antigens following uptake of apoptotic cells and induc-
tion of anergic or regulatory T cells [reviewed in [16,17]].
Through direct release of proinflammatory factors and
induction of proinflammatory Th1/Th17 effectors, DC
play an essential role in inflammatory/autoimmune con-
ditions. Therefore, the identification and characterization
of endogenous and/or exogenous anti-inflammatory
agents such as the n-3 fatty acids and their derivatives
represents an active field of research with significant
therapeutic potential. In the present study we determined
that exposure of conventional (myeloid) DC to DHA
contributes to the maintenance of an immature pheno-
type and prevents expression of proinflammatory cyto-
kines through PPARg activation and inhibition of NFB
nuclear translocation. We also observed a similar reduc-
tion of IL-12 family cytokines in vivo in splenic DC
obtained from mice maintained on a DHA-enriched diet.
Materials and methods
Mice
B10.A (6 to 10 weeks old) and C56BL/6 (4 weeks old)
mice were purchased from Jackson Laboratory (Bar Har-
bor, ME). Mice were handled and housed in accordance
with the guidelines of the Temple University Animal
Care and Use Committee.
Reagents
Lipopolysaccharide (LPS) (Escherichia coli O26:B6),
polyinosinic-polycytidylic acid (PolyI:C), peptidoglycan
(PGN), fluorescein isothiocyanate (FITC)-conjugated
dextran and streptavidin-peroxidase were purchased
from Sigma-Aldrich (St. Louis, MO). CD11c MicroBeads
were purchased from Miltenyi Biotec (Bergish-Gladbach,
Germany). CpG ODN 1826 was purchased from Invivo-
Gen (San Diego, CA). Recombinant murine GM-CSF,
IL-12, TNFa, IL-6 and CCL-4 were purchased from
Peprotech Inc (Rocky Hill, NJ). The ELISA kit for mur-
ine IL-27p28 was purchasedf r o mR & DS y s t e m s( M i n -
neapolis, MN). DHA, GW9662, Rosiglitazone (Rosi) and
peroxisome proliferator activated receptor g (PPARg)
transcription factor assay kit were purchased from Cay-
man Chemical (Ann Arbor, MI). Capture and biotiny-
lated anti-mouse IL-23 antibody were purchased from
eBioscience (San Diego, CA). FITC-conjugated anti-
mouse CD80, CD86, CD40, MHCII; recombinant mouse
IL-10; capture and biotinylated anti-mouse IL-12/p70,
IL-6, TNFa,I L - 1 0a n dC C L - 4 ;a n dT M BS u b s t r a t e
Reagent Set were purchased from BD PharMingen (San
Diego, CA). Nuclear extract kit and TransAm NFB p65
transcription factor assay kit were purchased from
Active Motif North America (Carlsbad, CA). Anti-IBa
mouse mAb were purchased from Cell Signaling Tech-
nology, Inc (Danvers, MA). Anti-GAPDH rabbit mAb
were purchased from Fitzgerald Industries International
(Concord, MA). Goat anti-rabbit and goat anti-mouse
antibodies conjugated to infrared dye were purchased
from LI-COR (Lincoln, NE).
Generation and purification of DC from bone marrow
DC were generated from bone marrow. Briefly, femur and
tibiae were removed from 6- to 8-wk-old male B10.A mice.
Both ends of the bones were cut open and bone marrow
cells were flushed out and washed with ice-cold RPMI
1640 medium (Invitrogen Life Technologies Research
Laboratory). 2 × 10
6 bone-marrow cells were cultured in
100 mm petri dishes containing 10 ml RPMI 1640 medium
supplemented with 10% heat-inactivated FBS (Atlanta Bio-
logicals, Norcross, GA), 2 mM L-glutamine, and 20 ng/ml
recombinant GM-CSF. After three days, another 10 ml of
complete medium containing GM-CSF was added to each
dish. On day 7 the non-adherent cells were harvested and
purified by immunomagnetic sorting with anti-CD11c-
coated magnetic beads using the autoMACS system
according to the manufacturer’s instructions (Miltenyi Bio-
tec). The purity of the sorted cells was determined by
FACS analysis (>96% for CD11c+ cells).
FACS Analysis
Cells were subjected to FACS analysis in a 3-color
FACSCalibur (BD Biosciences, Mountain View, CA).
Data were collected for 10,000 cells and analyzed using
Cellquest software from BD Biosciences (San Jose, CA).
DC were cultured in 12-well culture plates (1 × 10
6/ml)
and pretreated with 50 μMo fD H Af o r2 4h ,f o l l o w e d
by LPS (0.1 μg/ml) for an additional 24 h. DC were col-
lected, washed with PBS and incubated for 30 minutes
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CD40 FITC, anti-I-E
k FITC. The specificity of the pri-
mary Abs was established with appropriate isotype-
matched controls.
Endocytosis
Endocytosis was measured as the cellular uptake of
FITC-dextran (Sigma-Aldrich) and was quantified by
flow cytometry. Briefly, DC (5 × 10
5 cells/well) were
incubated in medium containing FITC-dextran (0.5 mg/
ml; molecular mass 40 kDa) for 2 h at 37°C. As a nega-
tive control, DC were precooled to 4°C prior to incuba-
tion with FITC-dextran at 4°C for 2 hours.
Subsequently, incubated cells were washed 3 times with
cold PBS and analyzed by FACS.
Cytokine and chemokine ELISA
Cytokine production was determined by sandwich
ELISA. DC were cultured in 12-well culture plates (1 ×
10
6cells/ml or 2 × 10
6 cells/ml) and pretreated with var-
ious concentration (0.1, 1, 10, 25, 50 μM) of DHA for
24 h, followed by LPS (0.1 μg/ml) for 12 or 24 h. Super-
natants were harvested and subjected to ELISA. The
detection limits were: 15 pg/ml for IL-6, TNFa, and IL-
10, 30 pg/ml for IL-23 and IL-12p70, 20 pg/ml for CCL-
4 and 4.7 pg/ml for IL-27.
Real-time RT-PCR
The expression of p19, p35, p40, IL-27p28, and EBI3
was detected by SYBR Green-based real-time RT-PCR.
RNA was prepared from 4 × 10
6 purified CD11c+ DC
using an Ultraspec RNA isolation system according to
the manufacturer’s instructions (Biotecx Laboratories,
Houston, TX). RNA (1 μg) was reversed transcribed to
cDNA and subjected to real time PCR. The PCR mix-
ture (20 μl), consists of 4 μl diluted cDNA, 16 μlo f
SYBR Green containing the PCR master mix and 150
nM of each primer. Real-time PCR was performed using
the Stratagene Mx3005P. The following primers were
used: p19 sense, 5’-TGCTGGATTGCAGAGCAGTAA-
3’ and antisense, 5’-ATGCAGAGATTCCGAGAGA-3’;
p35 sense, 5’-GAGGACTTGAA GATGTACAG-3’ and
antisense, 5’-TTCTATCTGTGTGAGGAGGGC-3’;p 4 0
sense, 5’-GACCCTGCCGATTGAACTGGC-3’ and anti-
sense, 5’-CAACGTTGCATCCTAGGA TCG-3’;p 2 8
sense, 5’-TCTGGTACAAGCTGGTTCCTGG-3’ and
antisense, 5’-TAGCCCTGAACCTCAGAGAGCA-3’;
EBI3 sense, 5’-GAGGGTCCGGCTTGATGAT T-3’ and
antisense, 5’-CACGGTGCCCTACATGCTAA-3’; b-actin
sense, 5’-TCCACCACCACAGCTGAGAGG-3’ and anti-
sense, 5’-CAGCTTCTC TTTGATGTCACG-3’.T h e
cycling conditions were 95°C for 15 s, 75°C for 1 min,
57°C for 30 sec, for 40 cycles, followed by a melting
point determination or dissociation curves. The expres-
sion level of each gene is indicated by the number of
cycles needed for the cDNA amplification to reach a
threshold. The amount of DNA is calculated from the
number of cycles by using standard curves and the
results are normalized to b-actin.
PPARg binding to PPRE containing oligonucleotides
Nuclear extracts were prepared as recommended by the
manufacturer (Cayman Chemicals) from 5 × 10
6 DC
treated as described in Results. The amounts of acti-
vated PPARg were determined by using an ELISA based
kit with immobilized oligonucleotides containing peroxi-
some proliferator responsive element (PPRE). 2 μg
nuclear extract were incubated in each well overnight at
4°C without agitation. Treatment with primary Ab speci-
fic for PPARg was followed by a secondary antibody
conjugated to HRP and colorimetric readout at 450 nm.
Detection antibodies and positive controls were pro-
vided with the manufacturer’s kit.
NFB translocation assay
DC were incubated in 50 μM DHA for 24 h and treated
with 0.1 μg/ml LPS for 1 h. Nuclear proteins were pre-
pared using the nuclear extract kit (Active Motif) accord-
ing to the manufacturer’s protocol. The amount of active
NFBp65 in the nuclear extract was detected using
ELISA based TransAM NFB kits containing immobi-
lized NFBp65 consensus site oligonucleotides. 5 μg
nuclear extract was added to each well, followed by pri-
mary antibodies that recognize a p65 epitope accessible
only in activated p65 bound to target DNA. An HRP-
conjugated secondary antibody provides a sensitive col-
orimetric readout quantified at 450 nm. Results are
expressed as relative activity, i.e. absorbance values above
those observed in samples with no LPS stimulation.
Cell extracts and Western blots
Whole cell extracts were generated by lysing DC in buf-
fer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS 1%
T r i t o nX - 1 0 0 ,1m MP M S F ,a n dp r o t e a s ei n h i b i t o r
cocktail (Sigma-Aldrich). Samples were run on SDS-
PAGE gels and transferred onto nitrocellulose mem-
brane. The membrane was probed with primary antibo-
dies against IBa and GAPDH, followed by infrared
conjugated secondary antibodies and scanned using the
ODYSSEY Infrared Imaging system (LI-COR).
In vivo experiments
4 wks old C57BL/6 mice (groups of 5) were fed with
control diet (no DHA) or DHA-enriched diet (0.22%
DHA) (Table 1) for 5 wks. 12 h after inoculation of 50
μg LPS i.p., expression of p40, p19, p35, p28 and EBI3
was determined by qRT-PCR in purified splenic CD11c
+ DC. The DHA supplement, under the trade name
DHASCO, was obtained from Martek Biosciences Cor-
poration (Columbia, MD). The diet was produced at
Research Diets Incorporated (New Brunswick, NJ).
Purification of splenic CD11c+ DC
Spleens cut into small pieces were incubated in HBSS
w/Ca
+2,M g
+2 containing 0.5 mg/ml Liberase TL and 1
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by filtering cells through cell strainers (70 μm). Spleen
CD11c+ DC were purified using the autoMACS system
and CD11c magnetic beads as recommended by the
manufacturer (Miltenyi Biotec).
Statistical analysis
Results are described as mean +/- SD. Comparisons
between two groups were done using Student t test,
whereas comparisons among multiple groups were done
by one way ANOVA. Statistical significance was deter-
mined as p values less than 0.05.
Results
DHA maintains an immature phenotype in DC
Increased expression of MHCII and costimulatory mole-
cules are hallmarks of DC maturation. To determine
whether DHA affects DC maturation, CD11c+ bone
marrow-derived DC were pretreated with DHA for 24 h
followed by LPS for an additional 24 h. Immature DC
displayed low levels of MHCII, CD40, CD80, and CD86,
and expression was dramatically increased following LPS
stimulation. DHA prevented the LPS-induced upregula-
tion of MHCII and costimulatory molecules (Fig. 1A).
In contrast to immature DC which take up antigens
efficiently, antigen uptake is significantly reduced in
mature DC. We investigated the effects of DHA on the
capacity of immature and LPS-matured DC to take up
FITC-dextran, and found that DHA prevented the
decrease in endocytosis following LPS treatment (Fig.
1B). Taken together, these results suggest that DHA
contributes to the maintenance of an immature status in
LPS-stimulated DC.
DHA prevents cytokine and chemokine release from LPS-
stimulated DC
In contrast to immature DC, LPS-treated DC secrete
proinflammatory cytokines and chemokines including
IL-12p70, IL-23, IL-6, TNFa, CCL3 and CCL4, and
anti-inflammatory cytokines such as IL-10. To investi-
gate the effect of DHA on cytokine/chemokine produc-
tion, we pretreated DC with DHA, followed by LPS
stimulation. DHA inhibited in a dose-dependent manner
the release of the IL-12 cytokine family, i.e. IL-12p70,
IL-23 and IL-27 (Fig. 2). We observed a similar DHA
inhibition of IL-6, TNFa, CCL-4, and IL-10 secretion in
LPS-stimulated DC (Fig. 3).
To investigate whether DHA could affect cytokine
production in response to signaling through various
TLRs, we pretreated DC with DHA, followed by stimu-
lation with LPS (TLR4 ligand), PGN (TLR2 ligand),
CpG (TLR9 ligand), poly I:C (TLR3 ligand) and com-
bined CpG and poly I:C treatment. We observed pro-
found inhibition of both IL-12p70 and IL-23 for LPS,
PGN and poly I:C stimulation, and reduction in cytokine
production for the combined CpG and poly I:C treat-
ment (Fig. 4).
DHA prevents IL-12p70 production through effects on
PPARg and NFB
In an effort to elucidate the transcriptional mechanisms
we focused on the peroxisome proliferator activated
receptor g (PPARg), which has the capacity to bind
unsaturated fatty acids including DHA, and on the
NFB signaling pathway.
DC were pretreated with increasing concentrations of
DHA for 24 h, followed by LPS stimulation. Nuclear
extracts were tested for PPARg activation by using a
PPARg regulatory sequence (PPRE)-containing oligonu-
cleotide binding assay. We observed high levels of
PPARg binding in DC treated with DHA concentrations
that were inhibitory for cytokine production (Fig. 5A).
The specificity of PPARg binding in DC treated with
DHA and LPS was confirmed by use of the specific
PPARg inhibitor GW9662, which reduced binding to
Table 1 Control and DHA diet analysis
Control Diet DHA Diet
gm% kcal% gm% kcal%
Protein 20 20 20 20
Carbohydrate 61 59 61 59
Fat 10 22 10 22
Total 100 100
kcal/gm 4.1 4.1
Ingredient gm kcal gm kcal
Casein, 80 Mesh 0 0 0 0
Casein, Alcohol Extracted 200 800 200 800
L-Cystine 3 12 3 12
Corn Starch 150 600 150 600
Maltodextrin 10 150 600 150 600
Sucrose 100 400 100 400
Dextrose 200 800 200 800
Cellulose, BW200 50 0 50 0
Soybean Oil 0 0 0 0
Safflower Oil, High Oleic 100 900 94.5 850.5
DHASCO (40% DHA) 0 0 5.5 49.5
t-BHQ 0.014 0 0.014 0
Mineral Mix S10022G 35 0 35 0
Vitamin Mix V10037 10 40 10 40
Choline Bitartrate 2.5 0 2.5 0
Total 1000.514 4152 1000.514 4152
Total composition of experimental diets per manufacturer’s analysis
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city, we used the PPARg agonist Rosi which induced
binding in DC treated with LPS in the absence of DHA
(Fig. 5B).
Next, we assessed the involvement of PPARg in the
DHA-mediated inhibition of cytokine production. The
PPARg inhibitor GW9662 did not affect LPS-induced
IL-12p70 production (Fig. 5C). PPARg activation by Rosi
prior to LPS treatment resulted in approximately 40%
reduction in IL-12p70 production. As expected, this
reduction was abolished by the PPARg inhibitor
GW9662 (Fig. 5C). Similar to Rosi, DHA pretreatment
resulted in a reduction in IL-12p70. However, in this
case, the reduction was only partially reversed by
GW9662 (Fig. 5C), an indication that other factors in
addition to PPARg mediate the inhibitory effect of DHA
on IL-12p70 production.
Since NFB is a major transcription factor for the
expression of cytokine/chemokine genes, we evaluated
t h ep o s s i b l er o l eo fD H Ao nN F Ba c t i v a t i o ni nL P S -
treated DC. Similar to the PPARg activation assay, we
prepared DC nuclear extracts and measured p65 binding
to oligonucleotides containing Bs p e c i f i cs e q u e n c e s .
DC treated with LPS exhibited high nuclear Bb i n d i n g
which was not affected by pretreatment with Rosi (Fig.
6A), which indicates that p65 nuclear translocation in
Figure 1 DHA maintains DC immature phenotype and high
endocytic capacity. CD11c+ DC (1 × 10
6/ml) were treated with 50
μM DHA for 24 h, followed by LPS (0.1 μg/ml) for another 24 h. (A)
Cells were analyzed for MHCII, CD40, CD80 and CD86 expression by
flow cytometry. One representative experiment of three is shown.
(B) DC were treated as in (A) and 5 × 10
5 cells were incubated with
FITC-dextran (0.5 mg/ml) at 4°C (negative control) or 37°C and
assessed for endocytosis by flow cytometry. Results are expressed as
percentage positive cells and geometric mean fluorescence (GMF)
+/- SD.
Figure 2 DHA prevents expression of IL-12 family cytokines in
LPS-treated DC.D C( 1×1 0
6/ml for IL-12p70 and IL-27 and 2 ×
10
6/ml for IL-23) were cultured in the presence of different
concentration of DHA for 24 h, followed by LPS for 12 h (for IL-23)
or 24 h (for IL-12p70 and IL-27). Supernatants were subjected to
ELISA. Data represent the mean +/- SD. * p < 0.01, #p < 0.05,
compared with LPS-treated samples (no DHA).
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Rosi, DHA reduced LPS-induced p65 binding by
approximately 50% (Fig. 6A). The inhibitory effect of
DHA on NFB translocation may be mediated through
the inhibition of IB degradation. Indeed, Western blots
confirmed that LPS induced a significant reduction in
IB, whereas DHA pretreated samples contained higher
IB levels (Fig. 6B).
In vivo effect of DHA on IL-12 family cytokine expression
Mice were maintained on a regular or DHA-enriched
diet for 5 weeks, followed by LPS inoculation. Splenic
DC were purified and analyzed for expression of IL-
12p40, IL-12p35, IL-23p19, IL-27p28 and IL-27EBI3.
With the exception of EBI3, all other IL-12 family cyto-
kine subunits were significantly reduced in splenic DC
from mice on the DHA-enriched diet (Fig. 7). This indi-
cates that, similar to our in vitro results, DHA affects
cytokine expression in vivo in splenic DC.
Discussion
The impact of diets rich in n-3 PUFAs and of DHA and
EPA administration has been evaluated in clinical stu-
dies and various animal models, with protective effects
described in models of colitis, sepsis, and stroke [18-24].
Confirming the protective anti-inflammatory effect of n-
3P U F A s ,t r a n s g e n i cfat-1 mice expressing a gene
encoding an n-3 fatty acid desaturase which enables
production of n-3 from n-6 PUFAs, exhibit low NFB
activity, reduced levels of TNFa and IL-1b, and are pro-
tected from colitis [25].
The direct effects of DHA or EPA on various immune
cell populations are not well studied. Initial reports indi-
cated that DHA favors Th2 differentiation which is in
agreement with its inhibitory effect on IL-12 production
by DC [13-15,26,27]. In the present study we report on
DHA effects on DC phenotype and function. In terms
of phenotype, DC treated with DHA and LPS maintain
an immature phenotype characterized by low expression
of MHCII and costimulatory molecules (CD40, CD80
and CD86). From a functional point of view these phe-
notypic traits result in poor stimulatory capacity for T
cells.
Exposure to DHA inhibited the production of proin-
flammatory molecules, i.e.I L - 6 ,T N F a,C C L - 4 ,a n do f
the anti-inflammatory cytokine IL-10. This is in agree-
ment with a report on human monocyte-derived DC
generated in the presence of DHA [14]. In contrast,
Loscher et al [28] reported that conjugated linoleic acid
inhibited LPS-induced IL-12 in murine DC through
upregulation of IL-10. Therefore, different PUFAs could
act through different molecular mechanisms to attenu-
ate the DC proinflammatory response. In agreement
Figure 3 DHA prevents cytokine production in LPS-treated DC.C D 1 1 c +D C( 2×1 0
6/ml for IL-10 or 1 × 10
6/ml for TNFa, IL-6 and CCL-4)
were treated with various concentrations of DHA for 24 h followed by LPS (0.1 μg/ml) for an additional 24 h. Supernatants were harvested and
assayed for IL-6, CCL-4, IL-10 and TNFa by ELISA. Two independent cultures were tested in triplicate. Results are expressed as mean +/- SD. * p <
0.01, #p < 0.05, compared to LPS-treated samples (no DHA).
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Page 6 of 10with several other reports [13-15,27], we found that
DHA had a profound inhibitory effect on IL-12p70 pro-
duction. In addition, we report here for the first time
that DHA has a similar inhibitory effect on the other
two members of the IL-12 family, i.e. IL-23 and IL-27.
IL-23 inhibition could have a significant impact on T
cell differentiation in terms of Th17, since IL-23 has
been reported to maintain the Th17 functional pheno-
type [29-32].
The intracellular signaling pathways elicited by DHA
and the final transcriptional targets are not known. One
possible mediator is PPARg, a nuclear receptor activated
by endogenous and exogenous ligands, with multiple
physiological functions, including immune regulation
[33-35]. Eicosanoids and PUFAs, including DHA, are
endogenous PPARg ligands [36,37]. Highly expressed in
DC, macrophages, T and B cells, PPARg acts primarily
as an anti-inflammatory agent [reviewed in [33-37]].
The model for ligand-dependent PPARg transrepression
of cytokine/chemokine gene expression in macrophages
and DC includes ligand-dependent SUMOylation of
PPARg followed by binding and stabilization of core-
pressor complexes resulting in maintenance of active
suppression of inflammatory genes [33]. We observed
that DHA concentrations that were effective for IL-12
inhibition also induced PPARg activation. The inhibitory
effect of DHA on IL-12p70 production was partially
reversed by the PPARg inhibitor GW9662. Taken
together, these results strongly suggest that the DHA
effect on DC expression of IL-12, and presumably other
cytokines as well, is mediated, at least partially, through
PPARg activation.
The partial reversal observed with the PPARg inhibitor
led us to consider the involvement of other factors
beside PPARg.S i n c eN F B, readily induced upon TLR
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Figure 4 Effects of DHA on IL-12p70 production initiated by
signaling through various TLRs. CD11c
+ DC (1 × 10
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IL-12p70 and 2 × 10
6 cells/ml for IL-23) were pretreated with 25 μM
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Figure 5 DHA activates PPARg. (A) CD11c+ DC (5 × 10
6)w e r e
pretreated with increasing concentrations of DHA for 24 h, followed
by 0.1 μg/ml LPS stimulation for 16 h. Activation of nuclear PPARg
was evaluated through binding to oligonucleotides containing PPRE
as described in Methods. (B) DC were pretreated with the PPARg
inhibitor GW9662 (10 μM) for 2 h, followed by 50 μM DHA or 1 μM
of the specific PPARg agonist Rosiglitazone (Rosi) for 24 h, and LPS
(0.1 μg/ml) for an additional 16 h. Activation of PPARg was
determined as described in (A). (C) CD11c+ DC (1 × 10
6/ml) were
pretreated with 4 μM GW9662 for 2 h before the addition of 5 μM
DHA or 0.4 μM Rosi (for 24 h) and LPS for an additional 24 h.
Supernatants were collected and IL-12p70 production was
determined by ELISA.
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kine/chemokine gene expression, we assessed the effect
of DHA on NFB activation. Our results indicate a
reduction of approximately 50% in the amounts of
nuclear p65 in DC treated with DHA and LPS, and the
reduction in p65 nuclear translocation correlates with
DHA-mediated IB stabilization.
Chronic activation of immune cells, including DC,
plays an essential role in inflammatory/autoimmune dis-
eases. In contrast to extensive knowledge regarding the
activation of the immune system, less is known about
endogenous and exogenous factors which contribute to
immune deactivation or return to homeostatic levels.
Recently, the n-3 unsaturated fatty acids emerged as sig-
nificant agents in resolving inflammation. Understanding
their actions on various immune cells will contribute to
a large degree to the future development of n-3 fatty
acids and/or their derivatives as potent anti-
inflammatory therapeutic agents in the prevention and
treatment of autoimmune/inflammatory conditions.
Conclusions
In this study, exposure of bone marrow-derived DC to
DHA resulted in the maintenance of an immature phe-
notype and drastic reduction in proinflammatory cyto-
kine release, particularly of the IL-12 cytokine family.
The effect of DHA on IL-12 expression was mediated
through activation of PPARg and inhibition of NFB.
Inhibition of IL-12 and IL-23 expression was also
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Figure 6 DHA blocks NFB p65 nuclear translocation.( A)1×
10
7DC were preincubated with (50 μM) DHA or (1 μM) Rosi for 24
h, followed by LPS treatment for 1 h. Presence of NFB p65 in DC
nuclear extracts was determined by binding to B containing
oligonucleotides. Results are expressed as relative activity, i.e.
absorbance values above those observed in the absence of LPS
stimulation. (B) DC were pretreated with DHA for 24 h, followed by
LPS stimulation for 40 min, and cell lysates were subjected to
Western blot analysis for IBa. Numbers represent relative
densitometric levels. One experiment out of three is shown.
E
B
I
3
/
-
a
c
t
i
n
0.0
0.2
0.4
0.6
0.8
1.0
Control Diet
DHA Diet
P
1
9
/
-
a
c
t
i
n
0.0
0.4
0.8
1.2
1.6
P<0.01
P<0.01
P<0.01
P
3
5
/
-
a
c
t
i
n
0.0
0.4
0.8
1.2
1.6
P<0.05
P
4
0
/
-
a
c
t
i
n
0.0
0.5
1.0
1.5
2.0
2.5 P<0.01
P<0.01
No LPS LPS
P
2
8
/
 
-
a
c
t
i
n
0
1
2
3
4
P<0.05
P<0.01
Figure 7 DHA prevents in vivo expression of IL-12 family
cytokines. C57BL/6 mice were maintained for 5 wks on regular or
DHA-enriched diet. Mice were injected i.p. with LPS (50 μg per
mouse) and 12 h later spleen CD11c+ DC were purified. Expression
of p40, p35, p19, p28 and EBI3 was determined by real time RT-PCR.
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Page 8 of 10evident in splenic DC from mice fed a DHA-enriched
diet, suggesting that dietary DHA acts as an anti-inflam-
matory agent in vivo.
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